header logo en

 

10 facts web


Study Of Avelumab In Combination

With Axitinib In Advanced Renal Cell

Cancer (JAVELIN Renal 100)

 
 
 Last updated: January 29, 2017
 STATUS: Recruiting (accepting new patients) (per ClinicalTrials.gov/NCT02493751)

WHO

is the trial for?

Patients with kidney cancer (Renal cell carcinoma, RCC) who currently meet the following criteria:

WHAT

is the key question that this trial is attempting to answer?

This phase-I study aims to evaluate the safety and tolerability of a new immune therapy combination for patients with kidney cancer.

This study investigates the antibody targeting programmed death ligand 1 (anti PD-L1) avelumab in combination with axitinib in patients with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC). Axitinib (InlytaTM) is a tyrosine kinase inhibitor, already approved for the treatment of advanced kidney cancer.

WHY

patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy that may be effective for kidney cancer. This trial will further support the research in kidney cancer and potentially help other patients with kidney cancer. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN

will the trial be open?

The study is open (recruiting) – 55 patients are currently expected to participate.

WHERE

is the trial available?

The trial will be available in cancer centres in the USA, UK and Japan.
For contact details, please click here.
pdf Trial Locations JAVELIN renal 100 (309 KB)
 

STUDY

DESIGN

What does the study look like?

Avelumab will be administered in combination with axitinib in different doses. Patients will be assigned a specific dose and will stay on treatment until the disease progresses or unacceptable side effects occur.

  • avelumab is an antibody targeting programmed death ligand 1 (anti PD-L1)
  • axitinib (Inlyta™) is an oral, small-molecule, tyrosine kinase inhibitor, already approved for the treatment of metastatic renal cell carcinoma
The Phase I trial is expected to report the best dose and regimen for safety and efficacy.

HOW

do I get more information?

Patient organisations supporting kidney cancer patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving kidney cancer patients. If there are no such organisations in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.

CONNECT

with other patients on this trial

If you want to connect with other patients considering or participating in this trial, you can find them here: List of organisations worldwide.

SHARE

your experience 

If you are participating on this trial and want to share your experiences, please feel free to send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience (with your name omitted) would be helpful for other patients and patient organisations.

RESULTS

of the study

No results are available at this time. Future results will be linked here.
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.
 
Back to clinical trials overview: How can I find an IO clinical trial for my cancer?